Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000472 Act: 34 Size: 605 KB 网页链接
$Sol-gel(SLGL)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-20-000457 Act: 33 Size: 878 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000453 Act: 34 Size: 138 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000277 Act: 34 Size: 4 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000270 Act: 34 Size: 149 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000090 Act: 34 Size: 263 KB 网页链接
$Sol-gel(SLGL)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-20-000087 Act: 33 Size: 724 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000061 Act: 34 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-20-000017 Act: 34 Size: 139 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-19-002987 Act: 34 Size: 148 KB 网页链接